ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cancer immunotherapy-focused Gritstone Oncology has launched with $102 million in its first round of financing, led by Versant Ventures, the Column Group, and Clarus Ventures. The sizable backing will allow Gritstone to develop personalized cancer vaccines based on tumor-specific neoantigens. These protein antigens are created by mutating tumors and thus can be recognized and attacked by the immune system. The Bay Area company will first target lung cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X